Aerocrine’s new instrument NIOX VERO and test kits will be used for diagnosing and monitoring patients with asthma.

Pursuant to the terms of the agreement, Intramedic will exclusively sell and distribute Aerocrine’s NIOX VERO and test kits in Sweden with effect from 1 January 2014.

In addition, the agreement includes Intramedic taking on the support, sales and distribution for the already installed base of Aerocrine’s NIOX MINO devices in Sweden.

Aerocrine international sales director Linus Norrbom noted as the company prepares to launch its new product NIOX VERO in Sweden, it is very pleased to partner with Intramedic.

"This deal is part of Aerocrine’s strategy of substantially growing the European business in a cost-efficient manner," Norrbom added.

Aerocrine offers versatile monitoring devices for fractional exhaled Nitric Oxide (FeNO)-testing.

The company’s NIOX VERO and NIOX MINO, the predecessor to NIOX VERO, devices offer added advantages for patient care, including detecting allergic airway inflammation, determining the likelihood of corticosteroid responsiveness, monitoring of airway inflammation to determine the potential need for corticosteroid, and unmasking of otherwise unsuspected non-adherence to corticosteroid therapy.

Intramedic has been exclusive distributing Aerocrine’s products in Denmark for a long time. The company has successfully launched the NIOX MINO in Denmark.